Carfilzomib-Pomalidomide-Dexamethasone (KPD) in Relapsed/Refractory Multiple Myeloma Patients - an Institutional Retrospective Analysis

被引：1
|
作者：
Mehta, Pallavi [1 ]
Yadav, Neha [1 ]
Bhaarat, Mohan [2 ]
Mirgh, Sumeet Prakash [3 ]
Khushoo, Vishvdeep [3 ]
Thekuddan, Shinto Francis [1 ]
Agrawal, Narendra [3 ]
Ahmed, Rayaz [4 ]
Bhurani, Dinesh [3 ]
机构：
[1] Rajiv Gandhi Canc Inst & Res Ctr, Dept Hematooncol, New Delhi, India
[2] Rajiv Gandhi Canc Inst, New Delhi, India
[3] Rajiv Gandhi Canc Inst & Res Ctr, Dept Hematooncol & BMT, New Delhi, India
[4] Rajiv Gandhi Canc Inst & Res Inst, New Delhi, India
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-131674
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5572
引用
收藏
页数：3
相关论文
共 50 条
  • [31] A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients
    Bringhen, Sara
    Magarotto, Valeria
    Liberati, Anna Marina
    Belotti, Angelo
    Larocca, Alessandra
    Gilestro, Milena
    Bonello, Francesca
    Gaidano, Gianluca
    Bertazzoni, Paola
    Stocchi, Raffaella
    Ribolla, Rossella
    Di Sano, Chiara
    Patriarca, Francesca
    Passera, Roberto
    De Paoli, Lorenzo
    Oliva, Stefania
    Cafro, Anna Maria
    Sonneveld, Pieter
    Palumbo, Antonio
    Boccadoro, Mario
    BLOOD, 2016, 128 (22)
  • [32] The mutational landscape underlying carfilzomib and pomalidomide resistance in relapsed/refractory multiple myeloma
    Xu, Jing
    Giesen, Nicola
    Paramasivam, Nagarajan
    Goldschmidt, Hartmut
    Brors, Benedikt
    Raab, Marc S.
    Weinhold, Niels
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E83 - E84
  • [33] Carfilzomib-Pomalidomide-Dexamethasone in Anti-CD38 Antibodies and Lenalidomide Relapse/Refractory Multiple Myeloma: A Real Life Monocentric Cohort
    Debureaux, Pierre-Edouard
    Talbot, Alexis
    Forgeard, Nathalie
    Elessa, Dikelele
    Theves, Floriane
    Royer, Bruno
    Desrayaud, Nathalie
    Citerne, Antoine
    Cuccuini, Wendy
    Chat, Laureen
    Arnulf, Bertrand
    Harel, Stephanie
    BLOOD, 2023, 142
  • [34] Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis
    Richardson, Paul G.
    Perrot, Aurore
    San Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Shang-Yi
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Mace, Sandrine
    Zhang, Rick
    Dubin, Franck
    Morisse, Mony Chenda
    Anderson, Kenneth C.
    REVISTA CHILENA DE LITERATURA, 2024, (109): : 2239 - 2249
  • [35] Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis
    Richardson, Paul G.
    Perrot, Aurore
    San Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Shang-Yi
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Mace, Sandrine
    Zhang, Rick
    Dubin, Franck
    Morisse, Mony Chenda
    Anderson, Kenneth C.
    HAEMATOLOGICA, 2024, 109 (07) : 2239 - 2249
  • [36] Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma ( RRMM) Patients
    不详
    BLOOD, 2021, 138
  • [37] Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)
    Badros, Ashraf Z.
    Hyjek, Elizabeth
    Ma, Ning
    Lesokhin, Alexander M.
    Rapoport, Aaron P.
    Kocoglu, Mehmet H.
    Lederer, Emily
    Philip, Sunita
    Lesho, Patricia
    Johnson, Ashlee
    Dell, Cameron
    Goloubeva, Olga
    Singh, Zeba
    BLOOD, 2016, 128 (22)
  • [38] Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy In Relapsed Or Refractory Multiple Myeloma
    Mark, Tomer M.
    Boyer, Angelique
    Rossi, Adriana C.
    Kwon, Dennis
    Pearse, Roger N.
    Zafar, Faiza
    Pekle, Karen
    Tegnestam, Linda
    Jayabalan, David
    Ely, Scott A.
    Coleman, Morton
    Chen-Kiang, Selina
    Niesvizky, Ruben
    BLOOD, 2013, 122 (21)
  • [39] ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma
    Mark, Tomer M.
    Boyer, Angelique
    Rossi, Adriana C.
    Shah, Manan
    Pearse, Roger N.
    Zafar, Faiza
    Pekle, Karen
    Tegnestam, Linda
    Sacris, Erlinda A.
    Greenberg, June
    Speaker, Stephanie
    Jayabalan, David
    Ely, Scott A.
    Coleman, Morton
    Chen-Kiang, Selina
    Niesvizky, Ruben
    BLOOD, 2012, 120 (21)
  • [40] Clarithromycin, pomalidomide, and dexamethasone (ClaPD) in relapsed or refractory multiple myeloma.
    Rossi, Adriana C.
    Mark, Tomer Martin
    Rodriguez, Melissa
    Shah, Manan
    Quinn, Ryann
    Pearse, Roger N.
    Zafar, Faiza
    Pekle, Karen
    Speaker, Stephanie
    Jayabalan, David
    Ely, Scott
    Coleman, Morton
    Chen-Kiang, Selina
    Niesvizky, Ruben
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345